At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
CNTX-6970 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.
In Brief
A Phase 2 clinical trial evaluating CNTX-6970 and Placebo for Knee Osteoarthritis. Completed, enrolled 55 participants across 16 sites.
Detailed Summary
The primary objective of this study is to evaluate the safety and efficacy of CNTX-6970 for the treatment of pain related to OA of the knee compared to placebo. CNTX-6970 is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKnee Osteoarthritis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartOct 2021
Primary CompletionJun 2024
TodayJul 2026
First PostedAug 27, 2021
Enrollment StartOct 25, 2021
Primary CompletionJun 11, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 4.8 years ago
Interventions
CNTX-6970drug
CNTX-6970, a novel potent antagonist of CCR2 with lesser effects on CCR5, is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
Placebodrug
BID